The goal of this clinical trial is to learn about the nature of brain abnormalities associated with excess body fat in healthy adults aged 35-55. The main questions it aims to answer are: * Will excessive fat be associated with brain abnormalities on MRI measures? * Will weight loss change brain health on MRI measures? Participants will: * Self-administer study drug, semaglutide, once a week for 80 weeks * Complete metabolic and basic body measurements * Complete cognitive, mood, and dietary assessments * Complete questionnaires * Undergo MRIs
Age range
35 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Serum C-reactive Protein (CRP)
Timeframe: Baseline & Change from Baseline
Serum Pro-inflammatory Cytokines (Interleukin-6, TNF-α, Interleukin-1β, and IL-1 Receptor Antagonist)
Timeframe: Baseline & Change from Baseline
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Timeframe: Baseline & Change from Baseline
Fasting Plasma Glucose
Timeframe: Baseline & Change from Baseline
Glycated Hemoglobin A1c (HbA1c)
Timeframe: Baseline & Change from Baseline
Serum Leptin
Timeframe: Baseline & Change from Baseline
Serum Ghrelin
Timeframe: Baseline & Change from Baseline
Serum Adiponectin
Timeframe: Baseline & Change from Baseline
Fasting Serum Insulin
Timeframe: Baseline & Change from Baseline
Serum Glucagon-Like Peptide-1 (GLP-1)
Timeframe: Baseline & Change from Baseline
Serum C-peptide
Timeframe: Baseline & Change from Baseline
Serum Lipid Panel (Total Cholesterol, HDL Cholesterol, LDL Cholesterol, Triglycerides, and Non-Esterified Fatty Acids [NEFA])
Timeframe: Baseline & Change from Baseline
Serum Apolipoprotein B (ApoB)
Timeframe: Baseline & Change from Baseline
Red Blood Cell Phospholipid Fatty Acid Composition
Timeframe: Baseline & Change from Baseline
Cerebral Blood Flow as Measured by Pseudo-Continuous Arterial Spin Labeling (pCASL) MRI
Timeframe: Baseline & Change from Baseline
Oxygen Extraction Fraction (OEF) as Measured by Quantitative Susceptibility Mapping (QSM) and T2* MRI
Timeframe: Baseline & Change from Baseline
Cerebral Metabolic Rate of Oxygen (CMRO₂) as Measured by QSM and T2* MRI
Timeframe: Baseline & Change from Baseline
Cortical Thickness as Measured by Structural MRI
Timeframe: Baseline & Change from Baseline
Grey Matter Volume as Measured by Structural MRI
Timeframe: Baseline & Change from Baseline
Grey Matter Surface Area as Measured by Structural MRI
Timeframe: Baseline & Change from Baseline
White Matter Fractional Anisotropy (FA) as Measured by Diffusion Tensor Imaging (DTI)
Timeframe: Baseline & Change from Baseline
White Matter Mean Diffusivity (MD) as Measured by Diffusion Tensor Imaging (DTI)
Timeframe: Baseline & Change from Baseline
White Matter Microstructure as Measured by NODDI (intracellular volume fraction [ICVF], isotropic volume fraction [ISOVF], and Orientation Dispersion Index [ODI])
Timeframe: Baseline & Change from Baseline
White Matter Hyperintensity Volume as Measured by FLAIR MRI
Timeframe: Baseline & Change from Baseline
Cerebrovascular Reactivity (CVR) as Measured by BOLD fMRI with End-Tidal CO₂ (EtCO₂) Challenge
Timeframe: Baseline & Change from Baseline
Neuroinflammation proxy as Measured by T2* relaxation times
Timeframe: Baseline & Change from Baseline
Neuromelanin Contrast Ratio in the Substantia Nigra as Measured by Neuromelanin-Sensitive MRI
Timeframe: Baseline & Change from Baseline
Intracranial Artery Lumen Diameter as Measured by Time-of-Flight MRA
Timeframe: Baseline & Change from Baseline
Body Mass Index (BMI)
Timeframe: Baseline & Change from Baseline
Waist Circumference, Hip Circumference
Timeframe: Baseline & Change from Baseline
Waist-to-height ratio, Waist-to-hip ratio
Timeframe: Baseline & Change from Baseline
Visceral Adipose Tissue as Measured by MRI
Timeframe: Baseline & Change from Baseline
Subcutaneous Adipose Tissue as Measured by MRI
Timeframe: Baseline & Change from Baseline
Body Composition
Timeframe: Baseline & Change from Baseline